EXAS · As filed with the SEC

Exact Sciences cash flow statement, by quarter

The statement as Exact Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025^† 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024^† 3 months ended Sep 30, 2024	Q2 2024^† 3 months ended Jun 30, 2024	Q1 2024 3 months ended Mar 31, 2024
Cash flows from operating activities:
Net loss	(85,955)^†	(19,594)^†	(1,185)^†	(101,215)	(864,585)^†	(38,236)^†	(15,808)^†	(110,228)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	32,114^†	31,708^†	31,097^†	29,960	29,046^†	30,336^†	29,687^†	30,632
Loss on non-marketable and marketable equity securities	—	—	—	—	—	657^†	(1,303)^†	2,418
Equity Securities, FV-NI, Gain (Loss)	(3,736)^†	7,581^†	2,136^†	(2,900)	(941)^†	(657)^†	1,303^†	—
Deferred tax benefit	(1,032)^†	501^†	(6)^†	(1,007)	(11,946)^†	(398)^†	428^†	1,797
Share-Based Payment Arrangement, Noncash Expense	55,642^†	51,623^†	55,783^†	54,618	49,203^†	48,757^†	56,555^†	60,370
Gain on settlements of convertible notes, net	0^†	0^†	—	—	(20,508)^†	0^†	(10,254)^†	0
Amortization of Intangible Assets	24,239^†	24,174^†	24,186^†	24,101	24,101^†	24,435^†	23,311^†	23,311
Impairment of long-lived and indefinite-lived assets	406^†	543^†	0^†	6,251	838,164^†	18,698^†	8,152^†	4,446
Gain (Loss) On Contingent Consideration From Disposition Of Asset	0^†	0^†	0^†	0	(2,568)^†	(3,100)^†	(3,800)^†	268
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	4,905^†	8,705^†	4,909^†	8,287	(1,020)^†	5,310^†	(13,239)^†	5,603
Non-cash lease expense	6,792^†	6,765^†	6,730^†	6,753	6,281^†	6,603^†	6,990^†	7,052
Other	—	—	—	—	—	—	—	229
Other Noncash Income (Expense)	(1,971)^†	2,873^†	3,993^†	2,001	918^†	1,230^†	(2,896)^†	—
Changes in assets and liabilities, net of effects of acquisition:
Accounts receivable, net	7,342^†	46,853^†	(73,014)^†	(30,072)	15,151^†	(509)^†	(23,365)^†	(37,536)
Inventory, net	(1,416)^†	6,713^†	5,106^†	(14,175)	(25,395)^†	(9,612)^†	1,161^†	(1,065)
Operating lease liabilities	—	—	—	—	—	(6,388)^†	(6,354)^†	(6,603)
Operating lease liabilities	(7,424)^†	(7,276)^†	(7,266)^†	(6,575)	(6,438)^†	(6,388)^†	(6,354)^†	—
Accounts payable and accrued liabilities	48,859^†	67,135^†	39,415^†	58,633	5,280^†	56,123^†	35,650^†	(53,515)
Increase (Decrease) in Other Operating Assets	6,400^†	(7,407)^†	(8,624)^†	3,837	4,035^†	(3,639)^†	(9,305)^†	6,586
Increase (Decrease) in Other Operating Liabilities	8,440^†	(626)^†	(7,219)^†	(5,814)	(1,389)^†	1,174^†	12,845^†	(2,904)
Net cash provided by operating activities	151,689^†	219,923^†	89,017^†	30,809	47,063^†	138,719^†	107,065^†	(82,311)
Cash flows from investing activities:
Purchases of marketable securities	0^†	(46,473)^†	(13,481)^†	(80,315)	(59,646)^†	(81,013)^†	(147,047)^†	(177,325)
Maturities and sales of marketable securities	201,795^†	40,053^†	252,872^†	77,557	54,905^†	70,581^†	36,357^†	43,978
Purchases of property, plant and equipment	(31,243)^†	(29,897)^†	(42,342)^†	(31,174)	(36,316)^†	(26,158)^†	(35,866)^†	(37,649)
Proceeds From Contingent Consideration Receivable	0^†	0^†	—	—	0^†	0^†	—	—
Proceeds From Sale Of Investments In Privately-Held Companies	—	—	—	—	0^†	—	—	—
Payments to Acquire Other Investments	(4,435)^†	(50,289)^†	—	—	(815)^†	1,726^†	1,047^†	(237)
Business combination, net of cash acquired and issuance costs	—	—	—	—	0^†	—	—	—
Other investing activities	0^†	152^†	650^†	(505)	0^†	(20)^†	237^†	(205)
Net cash provided by (used in) investing activities	91,117^†	(86,454)^†	224,895^†	(34,437)	(41,872)^†	(81,716)^†	(147,129)^†	(171,438)
Cash flows from financing activities:
Proceeds in connection with the Company's employee stock purchase plan	10,511^†	0^†	—	—	11,825^†	0^†	—	—
Proceeds from issuance of convertible notes	0^†	0^†	—	—	0^†	0^†	266,750^†	0
Repayments of Accounts Receivable Securitization	0^†	0^†	—	—	100,000^†	0^†	—	—
Repayments of convertible debt	498,344^†	0^†	0^†	(249,172)	0^†	0^†	0^†	—
Payment, Tax Withholding, Share-Based Payment Arrangement	—	209^†	293^†	(422)	—	2,132^†	43^†	(1,408)
Payment for Contingent Consideration Liability, Financing Activities	0^†	0^†	—	—	0^†	0^†	—	—
Other financing activities	(1,729)^†	(1,741)^†	(1,840)^†	(6,577)	(2,210)^†	(2,358)^†	(11,592)^†	(1,594)
Net cash provided by (used in) financing activities	(75,873)^†	(1,532)^†	(4,514)^†	(256,171)	10,499^†	(226)^†	224,603^†	(3,002)
Effects of exchange rate changes on cash and cash equivalents	26^†	1^†	574^†	290	(3,721)^†	1,873^†	(306)^†	(1,140)
Net increase (decrease) in cash, cash equivalents, and restricted cash	166,959^†	131,938^†	309,972^†	(259,509)	11,969^†	58,650^†	184,233^†	(257,891)
Cash, cash equivalents, and restricted cash, beginning of period	789,037	657,099	347,127	606,636	594,667	536,017	351,784	609,675
Cash, cash equivalents, and restricted cash, end of period	955,996	789,037	657,099	347,127	606,636	594,667	536,017	351,784
Non-cash investing and financing activities:
Property, plant and equipment acquired but not paid	5,509^†	(3,351)^†	(3,399)^†	17,523	1,817^†	(538)^†	(5,212)^†	17,654
Stock Issued During Period, Value, Employee Benefit Plan	0^†	0^†	0^†	43,943	0^†	0^†	0^†	—
Supplemental disclosure of cash flow information:
Interest paid	6,163^†	8,646^†	6,162^†	9,473	6,730^†	9,138^†	1,182^†	10,789

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.